Q-omics provides the consensus-scored ZNF667 profile across patient tissues and cancer cell-line models. ZNF667 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZNF667 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, ZNF667 RNA expression shows 19,065 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, COAD, and THYM as cancer lineages where ZNF667 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF667 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF667 survival associations across molecular data types. ZNF667 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF667 RNA expression–survival associations across cancer types. High ZNF667 expression shows unfavorable associations in LGG, but favorable associations in UVM, HNSC, LUAD, CESC and UCS. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZNF667 RNA expression.
This table summarizes ZNF667 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF667. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF667 shows lower tumor expression in COAD, KIRC, BRCA, KICH, STAD and HNSC. The COAD box plot shows higher ZNF667 RNA expression in normal versus tumor tissue (log2 FC = −0.279, t-test p < 0.001).
This table shows molecular features associated with ZNF667 in patient tissues and cancer cell lines. In patient samples, ZNF667 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF667 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BONE.
